Latest Breaking News On - Post marketing long term follow up study - Page 1 : comparemela.com

bluebird bio, Inc. announced the U.S. Food and Drug Administration has approved LYFGENIA?? , also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a.

Drug administrationTreatment centers qtcsQualified treatment centersPost marketing long term follow up study